Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

A Randomised Evaluation of Low-Dose Cytarabine Arabinoside Plus Lenalidomide Versus Single-Agent Low-Dose Cytarabine Arabinoside in Older Patients with Acute Myeloid Leukaemia: Results from the LI-1 Trial

Mhairi Copland, Cono Ariti, Ian Thomas, Laura Upton, Mia Sydenham, Priyanka Mehta, Shahidul Islam, Lars Kjeldsen, Alan K. Burnett, Robert Hills, Nigel H. Russell, Mike Dennis

Blood (2021) 138 (Supplement 1): 1266.

https://doi.org/10.1182/blood-2021-147802

Published: 2021

Journal Articles

Flow Cytometric Minimal Residual Disease As Risk Stratification Tool in Younger Adults with NPM1 Wild Type Standard Risk Acute Myeloid Leukemia

Sylvie D Freeman, MBChB, DPhil, Robert K. Hills, DPhil, Paul Virgo, Naeem Khan, PhD, Stephen Couzens, Richard James Dillon, MA, PhD MRCP, FRCPath, Laura Upton, Lars Kjeldsen, MD, Ian Thomas, David Grimwade, Alan K. Burnett, MD, Nigel H. Russell

Blood (2017) 130 (Supplement 1): 468.

https://doi.org/10.1182/blood.V130.Suppl_1.468.468

Published: 2017

Journal Articles

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML

Steven Knapper, Nigel Russell, Amanda Gilkes, Robert K. Hills, Rosemary E. Gale, James D. Cavenagh, Gail Jones, Lars Kjeldsen, Michael R. Grunwald, Ian Thomas, Heiko Konig, Mark J. Levis, Alan K. Burnett

Blood (2017) 129 (9): 1143–1154.

https://doi.org/10.1182/blood-2016-07-730648

Published: 2017

Includes: Supplemental data

Journal Articles

A Comparison of 1 or 2 Courses of High Dose Cytarabine As Consolidation in Younger Patients with AML: First Results of the UK NCRI AML17 Trial

Nigel H. Russell, MD, Robert K Hills, DPhil, Sylvie Freeman, PhDFRCPath, Steven Knapper, Lars Kjeldsen, MD PhD, Ian Thomas, Jamie Cavenagh, Paul Cahalin, Mary Frances McMullin, MD FRCPath, FRCP, Alan K. Burnett, MD FRCP

Blood (2015) 126 (23): 221.

https://doi.org/10.1182/blood.V126.23.221.221

Published: 2015

Journal Articles

An Operational Definition of Primary Refractory Acute Myeloid Leukaemia Which Allows Early Identification of Patients for Whom Allogeneic Stem Cell Transplantation Represents the Only Curative Therapy

Paul Ferguson, MBChB MRCP PhD, Robert K Hills, DPhil, Angela Grech, Sophie Betteridge, Lars Kjeldsen, MD PhD, Michael Dennis, FRCPath, Paresh Vyas, MD PhD, Alan K. Burnett, MD FRCP, Anthony H. Goldstone, FRCP, FRCPath, Donald Milligan, MD, Richard E. Clark, MD, Nigel H. Russell, MD, Charles Craddock, MDPhD

Blood (2015) 126 (23): 559.

https://doi.org/10.1182/blood.V126.23.559.559

Published: 2015

Journal Articles

A randomized comparison of daunorubicin 90 mg/m 2 vs 60 mg/m 2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients

Alan K. Burnett, Nigel H. Russell, Robert K. Hills, Jonathan Kell, Jamie Cavenagh, Lars Kjeldsen, Mary-Frances McMullin, Paul Cahalin, Mike Dennis, Lone Friis, Ian F. Thomas, Don Milligan, Richard E. Clark

Blood (2015) 125 (25): 3878–3885.

https://doi.org/10.1182/blood-2015-01-623447

Published: 2015

Includes: Supplemental data

Journal Articles

Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia

Mike Dennis, Nigel Russell, Robert K. Hills, Claire Hemmaway, Nicki Panoskaltsis, Mary-Frances McMullin, Lars Kjeldsen, Helen Dignum, Ian F. Thomas, Richard E. Clark, Don Milligan, Alan K. Burnett

Blood (2015) 125 (19): 2923–2932.

https://doi.org/10.1182/blood-2014-10-608117

Published: 2015

Includes: Supplemental data

Journal Articles

A Randomised Comparison of Daunorubicin 90mg/m 2 Vs 60mg/m 2 in AML Induction: Results from the UK NCRI AML17 Trial in 1206 Patients

Alan K. Burnett, MD, Nigel Russell, Robert K. Hills, MA MSc DPhil, Jonathan Kell, MD MB, Jamie Cavenagh, Lars Kjeldsen, MD PhD, Mary Frances McMullin, MDFRCPath, FRCP, Paul Cahalin, Mike Dennis, Donald Milligan, MD, Richard E Clark, MBBS MD

Blood (2014) 124 (21): 7.

https://doi.org/10.1182/blood.V124.21.7.7

Published: 2014

Journal Articles

A Randomised Comparison of the Sequential Addition of the FLT3 Inhibitor Lestaurtinib (CEP701) to Standard First Line Chemotherapy for FLT3-Mutated Acute Myeloid Leukemia: The UK Experience

Steven Knapper, DM, Robert K Hills, MA MSc DPhil, James D Cavenagh, MD, Lars Kjeldsen, MDPhD, Ann E. Hunter, MBBS, Richard E Clark, MBBS MD, Michael Dennis, MD, Donald Milligan, MD, Mark J Levis, MDPhD, Nigel Russell, Alan K. Burnett, MD

Blood (2014) 124 (21): 3736.

https://doi.org/10.1182/blood.V124.21.3736.3736

Published: 2014

Journal Articles

The ATRA Question In AML: Lack Of Benefit Overall Or In Any Molecular Subgroup In The NCRI AML16 Trial

Alan K. Burnett, MD, Robert K. Hills, MA, MSc, DPhil, Lone S. Friis, MD, PhD, Lars Kjeldsen, MD, PhD, Donald Milligan, MD, FRCP, FRCPath, Ann E. Hunter, MBBS, FRCP, FRCPath, Michelle Lazenby, Amanda F Gilkes, MSc, David Bowen, MD, PhD, Nigel Russell, MD

Blood (2013) 122 (21): 493.

https://doi.org/10.1182/blood.V122.21.493.493

Published: 2013

Journal Articles

Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia

Sif Gudbrandsdottir, Henrik Sverre Birgens, Henrik Frederiksen, Bjarne Anker Jensen, Morten Krogh Jensen, Lars Kjeldsen, Tobias Wirenfeldt Klausen, Herdis Larsen, Hans Torben Mourits-Andersen, Claus Henrik Nielsen, Ove Juul Nielsen, Torben Plesner, Stanislaw Pulczynski, Inge Helleberg Rasmussen, Dorthe Rønnov-Jessen, Hans Carl Hasselbalch

Blood (2013) 121 (11): 1976–1981.

https://doi.org/10.1182/blood-2012-09-455691

Published: 2013

Includes: Supplemental data

Journal Articles

Reduced Intensity Transplant May Improve Survival in Patients Over the Age of 40, Especially If a Sibling Donor Is Used: Pooled Analysis of 2454 Patients and 407 Transplants in the UK NCRI AML15 and AML16 Trials

Nigel H Russell, MD, Robert K. Hills, MA, MSc, DPhil, Lars Kjeldsen, MD, PhD, John L Yin, MD, Charles Craddock, Alan K Burnett, MD

Blood (2012) 120 (21): 231.

https://doi.org/10.1182/blood.V120.21.231.231

Published: 2012

Journal Articles

Allelic Methylation Levels of VTRNA2-1 Predict Outcome in Higher Risk MDS Patients Not Treated by Azacytidine.

Marianne B. Treppendahl, MD, Magnus Tobiasson, MD, Anni Aggerholm, PhD, Mohsen Karimi, PhD, Trine Silkjaer, MD, Lone S. Friis, MD, PhD, Mette K. Andersen, PhD, Lars Kjeldsen, MD, PhD, Mette S. Holm, MD, PhD, Eva Hellström-Lindberg, PhD, Kirsten Grønbæk, MD, DMSc

Blood (2012) 120 (21): 2394.

https://doi.org/10.1182/blood.V120.21.2394.2394

Published: 2012

Journal Articles

Do Results From Clinical Trials in Acute Myeloid Leukemia Reflect Clinical Reality? A Danish National Cohort Study of 813 Patients

Lene Sofie Granfeldt Ostgard, MD, Mette Nørgaard, MD, Henrik Sengeløv, MD, PhD, Lars Kjeldsen, MD, PhD, Lone S. Friis, MD, PhD, Morten K. Jensen, MD, Maria Kallenbach, MD, Jan M. Norgaard, MD, PhD

Blood (2012) 120 (21): 1477.

https://doi.org/10.1182/blood.V120.21.1477.1477

Published: 2012

Journal Articles

High Early Death Rate with Excellent Survival Beyond Day 30 in Acute Promyelocytic Leukemia Confirmed in Unselected Patients: Results of a Population-Based Registry Study

Jan M. Norgaard, MD, PhD, Lene Sofie Granfeldt Ostgard, MD, Eigil Kjeldsen, MD, Mette S. Holm, MD, PhD, Lars Kjeldsen, MD, PhD, Maria Kallenbach, MD, Marianne T. Severinsen, MD, PhD, Preben Johansen, MD, Lone S. Friis, MD, PhD, Duruta Weber, MD, PhD, Gitte Kerndrup, Birgitte Preiss, MD, Morten K. Jensen, MD, Inge H. Dufva, MD, Susanne Timshel, MD, Mette K. Andersen, MD, PhD, Ove J. Nielsen, MD, PhD

Blood (2012) 120 (21): 3542.

https://doi.org/10.1182/blood.V120.21.3542.3542

Published: 2012

Journal Articles

A Randomised Comparison of Clofarabine Versus Low Dose Ara-C As First Line Treatment for Older Patients with AML

Alan K Burnett, MD, ChB, FRCP, FRCPath, FMedSci, Nigel H. Russell, MD, Mary Frances McMullin, MD, Jonathan Kell, MD, MB, Sahra Ali, FRCPath, FRCP, BM, MRCP, MRCPath, Paul Moreton, Andrew H Wei, MBBS, PhD, Lars Kjeldsen, MD, PhD, Robert K. Hills, MA, MSc, DPhil

Blood (2012) 120 (21): 889.

https://doi.org/10.1182/blood.V120.21.889.889

Published: 2012

Journal Articles

A Comparison of Daunorubicin/Ara-C (DA) Versus Daunorubicin/Clofarabine (DClo) and Two Versus Three Courses of Total Treatment for Older Patients with AML and High Risk MDS: Results of the UK NCRI AML16 Trial

Alan K. Burnett, MD, Nigel H Russell, MD, Jonathan Kell, MD, MB, Lars Kjeldsen, MD, PhD, Donald Milligan, MD, FRCP, FRCPath, Paul Cahalin, Robert K. Hills, MA, MSc, DPhil

Blood (2012) 120 (21): 892.

https://doi.org/10.1182/blood.V120.21.892.892

Published: 2012

Journal Articles

Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome in AML

Marianne Bach Treppendahl, Xiangning Qiu, Alexandra Søgaard, Xiaojing Yang, Cecilie Nandrup-Bus, Christoffer Hother, Mette Klarskov Andersen, Lars Kjeldsen, Lars Möllgaard, Eva Hellström-Lindberg, Johan Jendholm, Bo T. Porse, Peter A. Jones, Gangning Liang, Kirsten Grønbæk

Blood (2012) 119 (1): 206–216.

https://doi.org/10.1182/blood-2011-06-362541

Published: 2012

Includes: Supplemental data

Journal Articles

Evaluation of Azacitidine in Transfusion-Dependent, Epo-Refractory Patients with Lower-Risk Myelodysplastic Syndrome,

Magnus Tobiasson, MD, Lena Brandefors, MD, Ingunn Dybedal, MD, PhD, Hege Garelius, MD, Michael Grövdal, MD, PhD, Inge Hoegh Dufva, MD, PhD, Lars Kjeldsen, MD, PhD, Lars Nilsson, MD, PhD, Astrid Olsnes Kittang, MD, PhD, Anna Porwit, MD, PhD, Leonie Saft, MD, Mette Skov Holm, MD, PhD, Lars Möllgård, MD, Phd, Eva Hellström-Lindberg

Blood (2011) 118 (21): 3798.

https://doi.org/10.1182/blood.V118.21.3798.3798

Published: 2011

Journal Articles

Extramedullary Leukemia and Myeloid Sarcoma in AML: Results From a Population-Based Registry Study of 2261 Patients

Lene S.G. Oestgaard, MD, Henrik Sengeloev, MD, PhD, Mette S. Holm, MD, PhD, Hans E. Johnsen, Marianne T. Severinsen, MD, PhD, Eigil Kjeldsen, MD, Olav J. Bergmann, MD, PhD, Lone S. Friis, MD, PhD, Morten K. Jensen, MD, PhD, Ove J. Nielsen, MD, PhD, Lars Kjeldsen, MD, PhD, Jan M. Norgaard, MD, PhD

Blood (2011) 118 (21): 2003.

https://doi.org/10.1182/blood.V118.21.2003.2003

Published: 2011

NARROW

A Randomised Evaluation of Low-Dose Cytarabine Arabinoside Plus Lenalidomide Versus Single-Agent Low-Dose Cytarabine Arabinoside in Older Patients with Acute Myeloid Leukaemia: Results from the LI-1 Trial

Flow Cytometric Minimal Residual Disease As Risk Stratification Tool in Younger Adults with NPM1 Wild Type Standard Risk Acute Myeloid Leukemia

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML

A Comparison of 1 or 2 Courses of High Dose Cytarabine As Consolidation in Younger Patients with AML: First Results of the UK NCRI AML17 Trial

An Operational Definition of Primary Refractory Acute Myeloid Leukaemia Which Allows Early Identification of Patients for Whom Allogeneic Stem Cell Transplantation Represents the Only Curative Therapy

A randomized comparison of daunorubicin 90 mg/m 2 vs 60 mg/m 2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients

Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia

A Randomised Comparison of Daunorubicin 90mg/m 2 Vs 60mg/m 2 in AML Induction: Results from the UK NCRI AML17 Trial in 1206 Patients

A Randomised Comparison of the Sequential Addition of the FLT3 Inhibitor Lestaurtinib (CEP701) to Standard First Line Chemotherapy for FLT3-Mutated Acute Myeloid Leukemia: The UK Experience

The ATRA Question In AML: Lack Of Benefit Overall Or In Any Molecular Subgroup In The NCRI AML16 Trial

Rituximab and dexamethasone vs dexamethasone monotherapy in newly diagnosed patients with primary immune thrombocytopenia

Reduced Intensity Transplant May Improve Survival in Patients Over the Age of 40, Especially If a Sibling Donor Is Used: Pooled Analysis of 2454 Patients and 407 Transplants in the UK NCRI AML15 and AML16 Trials

Allelic Methylation Levels of VTRNA2-1 Predict Outcome in Higher Risk MDS Patients Not Treated by Azacytidine.

Do Results From Clinical Trials in Acute Myeloid Leukemia Reflect Clinical Reality? A Danish National Cohort Study of 813 Patients

High Early Death Rate with Excellent Survival Beyond Day 30 in Acute Promyelocytic Leukemia Confirmed in Unselected Patients: Results of a Population-Based Registry Study

A Randomised Comparison of Clofarabine Versus Low Dose Ara-C As First Line Treatment for Older Patients with AML

A Comparison of Daunorubicin/Ara-C (DA) Versus Daunorubicin/Clofarabine (DClo) and Two Versus Three Courses of Total Treatment for Older Patients with AML and High Risk MDS: Results of the UK NCRI AML16 Trial

Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome in AML

Evaluation of Azacitidine in Transfusion-Dependent, Epo-Refractory Patients with Lower-Risk Myelodysplastic Syndrome,

Extramedullary Leukemia and Myeloid Sarcoma in AML: Results From a Population-Based Registry Study of 2261 Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only